Acquisition of Cialis (Tadalafil) rights in Hong Kong, Macau, and South Korea.
This acquisition signifies Zuellig Pharma's strategic expansion into the men's health market in key Asian territories. By securing rights to a well-established brand like Cialis, the company aims to leverage its existing distribution networks and market expertise to drive growth and cater to an unmet medical need, potentially increasing revenue and market share in these regions.
The acquisition focuses on Hong Kong, Macau, and South Korea, representing significant markets within East Asia. This move allows Zuellig Pharma to strengthen its presence in the region's pharmaceutical landscape, particularly in the growing men's health segment, and capitalize on local market dynamics.
The acquisition covers Hong Kong, Macau, and South Korea.
This expands Zuellig Pharma's men's health product portfolio in Asia.
Zuellig Pharma acquired Cialis (Tadalafil) rights from Eli Lilly.
The acquisition covers Hong Kong, Macau, and South Korea.
This expands Zuellig Pharma's men's health product portfolio in Asia.
Zuellig Pharma has acquired all rights to Cialis (Tadalafil), a leading men's health product, from Eli Lilly and Company in Hong Kong, Macau, and South Korea. This strategic acquisition expands Zuellig Pharma's portfolio in the men's health sector within these key Asian markets, aiming to enhance its market presence and product offerings.
Sign in to save notes on signals.
Sign In